Stock comparison
Genmab A/S
UFP Technologies
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
UFPT
UFP Technologies
Market cap
$1.77B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | UFPT | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 64C | GMAB |
| Benjamin Graham | 64C | 79B | UFPT |
| Philip Fisher | 48D | 64C | UFPT |
| Peter Lynch | 25F | 62C | UFPT |
| Joel Greenblatt | 76B | 43D | GMAB |
| Charlie Munger | 68C | 50C | GMAB |
| Terry Smith | 71C | 52D | GMAB |
Side-by-side metrics
| Metric | GMAB | UFPT |
|---|---|---|
| Market cap | $16.5B | $1.77B |
| P/E (TTM) | 6.2x | 24.4x |
| EV/EBIT | 12.0x | 19.7x |
| ROIC (TTM) | 43.78% | 12.31% |
| Gross margin | 93.88% | 28.35% |
| Net margin | 18.23% | 11.27% |
| Revenue CAGR 5y | -18.45% | 30.74% |
| EPS CAGR 5y | -23.48% | 43.19% |
| Debt / Equity | 0.1x | 0.4x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Market cap$16.5Bvs $1.77B+89%
- Debt / Equity0.1xvs 0.4x+79%
- P/E (TTM)6.2xvs 24.4x+75%
- ROIC (TTM)43.78%vs 12.31%+72%
UFPT leads on
- Revenue CAGR 5y30.74%vs -18.45%+160%
- EPS CAGR 5y43.19%vs -23.48%+154%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.